FDA approval of paroxetine for menopausal hot flushes

N Engl J Med. 2014 May 8;370(19):1777-9. doi: 10.1056/NEJMp1402080.

Authors

Ronald J Orleans¹, Li Li, Myong-Jin Kim, Jia Guo, Mahboob Sobhan, Lisa Soule, Hylton V Joffe

Affiliation

¹ From the Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

PMID: 24806158
DOI: 10.1056/NEJMp1402080

No abstract available

MeSH terms

Advisory Committees
Antineoplastic Agents, Hormonal / therapeutic use
Cytochrome P-450 CYP2D6 / drug effects
Drug Approval*
Drug Interactions
Female
Hot Flashes / drug therapy*
Humans
Paroxetine / pharmacology
Paroxetine / therapeutic use*
Selective Serotonin Reuptake Inhibitors / pharmacology
Selective Serotonin Reuptake Inhibitors / therapeutic use*
Suicidal Ideation*
Tamoxifen / therapeutic use
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents, Hormonal
Serotonin Uptake Inhibitors
Tamoxifen
Paroxetine
Cytochrome P-450 CYP2D6